Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Leucovorin

Aliases
Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin (50 other aliases)

60 clinical trials

1 drug

85 indications

Indication
Gastroesophageal Adenocarcinoma
Indication
Healthy Participants
Indication
Leukemia
Indication
Breast Cancer (HER2-positive)
Indication
HER2-positive Gastric Cancer
Indication
HER2-positive solid tumors
Indication
ERBB2 Amplification
Indication
Colorectal Cancer
Indication
Advanced Solid Tumor
Indication
Cancer
Indication
Solid Tumor
Indication
Cholangiocarcinoma
Indication
Bladder Cancer
Indication
Ovarian Cancer
Indication
Stomach Cancer
Indication
Palpable Subcutaneous Malignant Lesions
Indication
Renal Cell Carcinoma
Indication
Melanoma
Indication
Primary Peritoneal Cancer
Indication
Fallopian tube cancer
Indication
Stomach Adenocarcinoma
Indication
Gastric Esophageal Cancer
Indication
Pancreatic Adenocarcinoma
Indication
HER2-expressing Gastrointestinal Cancers
Indication
Esophageal Cancer
Indication
Pancreatic adenocarcinoma
Indication
Bile Duct Cancer
Indication
Advanced Solid Tumours
Indication
Non-small Cell Lung Carcinoma
Indication
Head and Neck Neoplasms
Indication
Gastric Adenocarcinoma
Indication
Gastric or Gastroesophageal Junction Adenocarcinoma
Indication
Pancreatic Ductal Adenocarcinoma
Indication
Pancreatic Cancer
Indication
Advanced Gastrointestinal Cancer
Indication
Oncology
Indication
Biliary Tract Cancer
Indication
Endometrial Cancer
Indication
Gastroesophageal Cancer
Indication
Solid Tumors
Indication
Esophageal adenocarcinoma
Indication
Liver Metastases
Indication
Rectal Cancer
Indication
Recurrent Rectal Cancer
Indication
Colon Cancer
Indication
Pancreatic Acinar Cell Adenocarcinoma
Indication
Stage IIB Pancreatic Cancer
Indication
Adult T Acute Lymphoblastic Leukemia
Indication
Stage II Adult Lymphoblastic Lymphoma
Indication
Childhood Lymphoblastic Lymphoma
Indication
Ann Arbor Stage III Adult Lymphoblastic Lymphoma
Indication
Stage IV Adult Lymphoblastic Lymphoma
Indication
Stage IV Childhood Lymphoblastic Lymphoma
Indication
Childhood Acute Lymphoblastic Leukemia
Indication
Stage I Gastric Cancer AJCC v8
Indication
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Indication
Gastroesophageal Junction Adenocarcinoma
Indication
Stage III Gastric Cancer
Indication
Gastric Cancer AJCC v8
Indication
Stage III Pancreatic Cancer
Indication
Chemotherapy effects
Indication
Chemotherapy-induced toxicity
Indication
Acute Lymphoblastic Leukemia
Indication
Acute Undifferentiated Leukemia
Indication
Colorectal cancer
Indication
Colorectal Cancer stage IV AJCC v8
Indication
Stage IVA Colorectal Cancer AJCC v8
Indication
Stage IVB Colorectal Cancer AJCC v8
Indication
Stage IVC Colorectal Cancer AJCC v8
Indication
Locally Advanced Rectal Cancer
Indication
Stage IIIA Gastric Cancer AJCC v7
Indication
Stage IV Gastric Cancer
Indication
Peritoneal Cancer
Indication
Leukemia, Acute Lymphoblastic, in Remission
Indication
Philadelphia Chromosome Negative
Indication
BCR-ABL1-like
Indication
Testicular Leukemia
Indication
Stage III Colon Cancer
Indication
Esophageal cancer
Indication
Gallbladder Cancer
Indication
Small Bowel Adenocarcinoma
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
KRAS p.G12C
Indication
Pancreatic Ductal Carcinoma
Drug
leucovorin
Indication
Gastric Cancer
Clinical trial
Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
Status: Active (not recruiting), Estimated PCD: 2026-02-02
Clinical trial
An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State BMS-986322 on the Pharmacokinetics of Rosuvastatin (Part 1), the Pharmacokinetics and Pharmacodynamics of Metformin (Part 2) and the Pharmacokinetics of Methotrexate (Part 3) in Healthy Participants
Status: Completed, Estimated PCD: 2023-12-13
Clinical trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-26
Clinical trial
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-12-25
Clinical trial
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)
Status: Active (not recruiting), Estimated PCD: 2025-11-28
Clinical trial
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.
Status: Recruiting, Estimated PCD: 2025-05-02
Clinical trial
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Status: Active (not recruiting), Estimated PCD: 2022-07-23
Clinical trial
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-29
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
Status: Recruiting, Estimated PCD: 2026-11-10
Clinical trial
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Status: Active (not recruiting), Estimated PCD: 2024-08-24
Clinical trial
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
Status: Recruiting, Estimated PCD: 2025-01-06
Clinical trial
A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination With Either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab TWINPEAK Study
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Status: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).
Status: Completed, Estimated PCD: 2020-04-28
Clinical trial
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Status: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2021-02-15
Clinical trial
A Phase 1, Two-part, Open-label, Drug-drug Interaction Study in Healthy Male Adult Participants to Evaluate the Effects of BMS-986371 on the Pharmacokinetics of Methotrexate in the Presence and Absence of Sulfasalazine
Status: Completed, Estimated PCD: 2022-11-17
Clinical trial
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)
Status: Completed, Estimated PCD: 2021-09-08
Clinical trial
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-03-11
Clinical trial
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin Protocols
Status: Completed, Estimated PCD: 2021-05-15
Clinical trial
An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2021-02-01
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-11-28
Clinical trial
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Completed, Estimated PCD: 2019-03-01
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-27
Clinical trial
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver
Status: Completed
Clinical trial
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Status: Active (not recruiting), Estimated PCD: 2020-03-31
Clinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer
Status: Completed, Estimated PCD: 2013-08-01
Clinical trial
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II, Prospective, Multicenter Study of Cadonilimab in Combination With FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer.
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)
Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Status: Active (not recruiting), Estimated PCD: 2022-05-10
Clinical trial
A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-06
Clinical trial
Selective Treatment With Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined With Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Terminated, Estimated PCD: 2020-04-02
Clinical trial
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Terminated, Estimated PCD: 2015-12-23
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Clinical trial
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
Status: Withdrawn, Estimated PCD: 2023-08-01
Clinical trial
A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-08-19
Clinical trial
A Phase Ib/II Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer
Status: Withdrawn, Estimated PCD: 2023-01-31
Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Status: Not yet recruiting, Estimated PCD: 2028-12-03
Clinical trial
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Status: Completed, Estimated PCD: 2022-12-27